candesartan has been researched along with fluorobenzenes in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Li, D; Mehta, JL; Schaefer, RF | 1 |
| Chen, J; Li, D; Mehta, JL; Schaefer, R | 1 |
| Doerfler, A; Engelhorn, T; Heusch, G; Schulz, R | 1 |
| Kawachi, H; Khadzhynov, D; Krämer, S; Kron, S; Loof, T; Martini, S; Morgera, S; Neumayer, HH; Peters, H; Shimizu, F; Wang-Rosenke, Y | 1 |
| Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC | 1 |
| Erdogdu, O; Eriksson, L; Nyström, T; Sjöholm, Å; Zhang, Q | 1 |
| Carson, PE; Granger, CB; Jhund, PS; Kjekshus, J; Komajda, M; Kristensen, SL; Køber, L; McKelvie, RS; McMurray, JJ; Pfeffer, MA; Solomon, SD; Swedberg, K; Wedel, H; Wikstrand, J; Yusuf, S; Zile, MR | 1 |
| Rossignol, P; Zannad, F | 1 |
| Abdul-Rahim, AH; Fulton, RL; Jhund, PS; Kjekshus, J; Latini, R; Lees, KR; Lip, GY; Maggioni, AP; McMurray, JJ; Perez, AC; Tavazzi, L; Tognoni, G; Wikstrand, J | 1 |
1 review(s) available for candesartan and fluorobenzenes
| Article | Year |
|---|---|
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 1; Fatty Acids, Omega-3; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Stroke Volume; Sulfonamides; Tetrazoles | 2015 |
1 trial(s) available for candesartan and fluorobenzenes
| Article | Year |
|---|---|
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Canada; Europe; Female; Fluorobenzenes; Geography; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Russia; Stroke Volume; Sulfonamides; Tetrazoles; Treatment Outcome; United States | 2015 |
8 other study(ies) available for candesartan and fluorobenzenes
| Article | Year |
|---|---|
Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Benzimidazoles; Biphenyl Compounds; CD40 Antigens; Cholesterol; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Renin-Angiotensin System; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Tetrazoles | 2006 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebral Infarction; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Treatment Outcome | 2006 |
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fluorobenzenes; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Male; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Diabetes Mellitus; Disease Models, Animal; Fluorobenzenes; Glycation End Products, Advanced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |
The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipid Metabolism; Male; Mice; Mice, Knockout; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Streptozocin; Sulfonamides; Tetrazoles | 2010 |
Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells.
Topics: Apoptosis; Benzimidazoles; Biphenyl Compounds; Cardiotonic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Fluorobenzenes; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones | 2012 |
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Topics: Benzimidazoles; Biphenyl Compounds; Female; Fluorobenzenes; Geography; Heart Failure; Humans; Internationality; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Patients; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Stroke Volume; Sulfonamides; Tetrazoles | 2015 |